Science inspired by nature. Driven by nature.

Innovating Venom-Derived Therapeutics to Transform Cancer Care

Celtic Biotech is a clinical-stage biopharmaceutical company developing first-in-class peptide therapies from venom proteins to treat cancer and improve patient outcomes.

Biotech Company of the Year at the 2025 Pharma Industry Awards
Explore Our Pipeline Investor Overview

Our Lead Candidate

CB-24

A novel peptide therapy designed to target solid tumors and improve patient outcomes.

Learn More
Funded by the European Union

US National Academy of Medicine
Global Grand Challenge Health Longevity Award

Assistance Publique Immunoclin European Medicines Agency European Union Reptile Zoo Soochow University InterTradeIreland European Innovation Council EIT Health AICRI Instituto Butantan Enterprise Ireland AP-HP Sorbonne Université University of Galway

Our Pipeline

Building a future of better outcomes through innovative peptide therapeutics.

View Full Pipeline
CB-24
CB-4
CB-6
CB-25
Cancer Detection
Science, Innovation, and Impact diagram
Discover Our Science

Targeted Precision

Designed to attack cancer, not healthy cells.

Learn More